NCT04855565View on ClinicalTrials.gov

ALY688-SR in Generally Healthy Overweight or Obese Adults

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 19, 2021

Primary Completion Date

August 3, 2021

Study Completion Date

August 3, 2021

Conditions
Overweight and Obesity
Interventions
DRUG

ALY688-SR

single dose subcutaneous injection

Trial Locations (1)

3004

Nucleus Network, Melbourne

Sponsors
All Listed Sponsors
collaborator

INC Research Australia Pty Ltd

UNKNOWN

lead

Allysta Pharmaceutical

INDUSTRY

NCT04855565 - ALY688-SR in Generally Healthy Overweight or Obese Adults | Biotech Hunter | Biotech Hunter